Physician profile
Cristina Beatrice Bartis
NPI 1043422587
$5,277.16
in general payments reported to CMS, 2019-2025
37 companies · $622 in 2025
The $622 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $691 · 2021: $1,002 · 2022: $1,040 · 2023: $745 · 2024: $652 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,380.43 | 2019-2025 | Proclaim, Eterna |
| Kls-Martin L.P. | $484.85 | 2021-2023 | |
| Si-Bone, INC. | $371.16 | 2019-2025 | |
| Nevro Corp. | $210.92 | 2019-2021 | |
| Pfizer INC. | $188.34 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $157.06 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.54 | 2021-2024 | Relistor |
| Nalu Medical, INC. | $142.26 | 2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $134.34 | 2022 | |
| Stimwave Technologies Incorporated | $119.80 | 2021 | |
| Forte Bio-Pharma LLC | $99.91 | 2022 | |
| Collegium Pharmaceutical, INC. | $97.36 | 2019-2023 | Belbuca |
| Vertex Pharmaceuticals Incorporated | $88.60 | 2024-2025 | |
| Painteq LLC | $54.08 | 2022-2024 | Painteq |
| Medtronic USA, INC. | $53.54 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $46.09 | 2019-2022 | |
| Ibsa Pharma INC. | $42.87 | 2020-2023 | Tirosint, Licart |
| Interventional Pain Technologies INC. | $39.29 | 2021 | |
| Redhill Biopharma INC. | $37.61 | 2022 | |
| Depuy Synthes Sales INC. | $33.22 | 2024 | Monovisc, Orthovisc |
| Abbvie INC. | $31.84 | 2021-2024 | |
| Zyla Life Sciences, INC. | $31.51 | 2019 | |
| Bolton Medical INC | $31.06 | 2024 | Treo Abdominal Stent-Graft System |
| Ferring Pharmaceuticals INC. | $26.25 | 2025 | Euflexxa |
| Amgen INC. | $24.67 | 2019-2020 | |
| Trevena, INC. | $22.63 | 2023 | Olinvyk |
| Averitas Pharma INC. | $21.02 | 2024 | Qutenza |
| Protega Pharmaceutials INC | $20.29 | 2023 | Roxybond |
| Boston Scientific Corporation | $19.92 | 2019 | |
| Neuronetics, INC. | $18.47 | 2019 | |
| Tonix Medicines, INC. | $15.67 | 2025 | Tonmya |
| Spr Therapeutics, INC | $15.24 | 2024 | Sprint Pns System |
| Acacia Pharma INC | $15.14 | 2021 | |
| Spinal Simplicity, LLC | $14.44 | 2024 | Ha Minuteman G3-R |
| Shionogi INC | $13.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.76 | 2019 | |
| Mdd US Operations, LLC | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristina Bartis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.